NANJING, China, April 27, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, announced today that the Company filed its annual report on Form 20-F for the year ended December 31, 2012 with the Securities and Exchange Commission on April 26, 2013, U.S. Eastern Time. The annual report can be accessed on the Company's investor relations website at http://ir.simcere.com. The Company will provide a hard copy of the annual report containing its audited financial statements for the year ended December 31, 2012, free of charge, to its shareholders and ADS holders upon request.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group ("Simcere") (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:

Email: ir@simcere.com

    In Nanjing:                          In the United States:

    Jie Liu D'Elia                       Cindy Zheng

    Vice President                       Brunswick Group LLC

    Simcere Pharmaceutical Group         Tel: 1-212-333-3810

    Tel: 86-25-8556-6666*8857


    In Beijing:

    Yue Yu

    Brunswick Group

    Tel: 86-10-5960-8600

SOURCE Simcere Pharmaceutical Group